# Study to Assess the Safety and Efficacy of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)

> **NCT01253512** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Thrombotech Ltd.** · enrollment: 22 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** THR-18
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01253512
- **Lead sponsor:** Thrombotech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-03
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2010-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01253512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01253512, "Study to Assess the Safety and Efficacy of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01253512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*